You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Delivery of chemically modified PNA oligomers

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Improving data capture in clinical research using a chatbot

    SBC: Dokbot, LLC            Topic: NLM

    PROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents

    SBC: Grannus Therapeutics LLC            Topic: NCI

    Abstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Developing high throughput measurement of thiopurine in DNA by mass spectrometry

    SBC: Tymora Analytical Operations, LLC            Topic: 400

    PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)

    SBC: Tymora Analytical Operations, LLC            Topic: NIA

    PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Programming Metabolically Fit TILs for Immunotherapy

    SBC: Lipo-immuno Tech, LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government